Market Research Report
Global Prostate Cancer Biomarker Market - 2021-2028
|Global Prostate Cancer Biomarker Market - 2021-2028|
Published: October 11, 2021
Content info: 180 Pages
Delivery time: 2 business days
The global prostate cancer biomarker Market size was valued at US$ YY million in 2020 and is estimated to reach US$ YY million by 2028, growing at a CAGR of YY % during the forecast period (2021-2028).
Biomarkers are "chemicals" that can be used to detect both normal and pathological bodily processes. Prostate-specific antigen is one of the most well-known (PSA). For decades, the PSA test, which detects abnormally high PSA levels in the blood, has been used to screen for prostate cancer and possibly discover it early.
The factors driving the global prostate cancer biomarker market growth are the rising incidence of prostate cancer and the increasing awareness regarding diagnostic prostate cancer biomarker usage.
Prostate cancer biomarker is the second most frequent cancer among men and the fourth most prevalent cancer in the general population. In 2018, there were 1.3 million new cases. According to GLOBOCAN 2018 estimates, 1,276,106 new cases of prostate cancer were reported worldwide in 2018, with developed nations having a greater prevalence.
Elevated plasmatic levels of prostate-specific antigen (PSA > 4 ng/mL), a glycoprotein usually expressed by prostate tissue, are used to detect many prostate malignancies. However, because men without cancer have been identified with increased PSA levels, a tissue biopsy is the gold standard for confirming the existence of malignancy. Diagnostic prostate cancer biomarker growth and progression are influenced by diet and physical exercise. Dietary variables are primarily responsible for the reported global and ethnic disparities in prostate cancer biomarker incidence rates. Biomarkers are "chemicals" that can be used to detect both normal and pathological bodily processes. Hence, with prostate cancer's increasing incidence rate, the screening procedure using prostate biomarkers is also expected to increase.
In men, prostate cancer biomarker is the second most common cause of cancer-related mortality. Several factors create severe challenges in creating viable therapeutic modalities and screening methods for cancer detection and treatment, despite the current improved understanding of the molecular pathways leading to advanced metastatic illness. Prostate cancer biomarker cells undergo a series of genetic and epigenetic changes that lead to abnormal proliferation, angiogenesis, apoptosis evasion, secondary site metastasis, and androgen independence. These pro-oncogenic pathways and critical signalling molecules are currently being investigated at the molecular and cellular levels; with the application of this sophisticated technology to individual tumours, new markers identifying distinct tumour features in individual patients should be identified. The ability to characterise such indicators on a tailored level of analysis is likely to significantly impact how doctors diagnose early prostate cancer and intervene to reduce its prognosis.
Men have long been screened for prostate cancer using the prostate-specific antigen (PSA) biomarker. PSA cancer-specific sensitivity and present specificity challenges; nevertheless, a new generation of PCa biomarkers is emerging, consisting of serum-, urine-, and tissue-based assays that may enhance or eventually replace PSA testing. New genomic technologies have provided an additional interpretation of the specific patient's tumour biology, which has aided in identifying and developing these biomarkers. Several biomarkers are now commercially available with particular indications for illness diagnosis, prediction, prognosis, and therapy response.
Recent breakthroughs in targeted medicines have prompted hopes that using biomarkers in clinical settings will enhance patient outcomes while potentially saving money. Regardless of the cost-effectiveness of matching medicines, the cost-effectiveness of biomarkers remains unknown. According to the study, the average cost of treatment for a person with prostate cancer following diagnosis is around $2,800 per month. However, depending on whether the patient is insured or not, the sort of insurance or government aid one receives, and the precise type of treatment one requires, these prices can be greater or lower. Costs can also range depending on which country and the facilities one patient uses.
COVID-19 has affected the healthcare industry moderately. To stop its spread, government-imposed lockdown. People are fearful they may experience occupational effects and negative health from the COVID-19 pandemic. The stepwise procedure for localised prostate cancer starts with determining a diagnosis using a PSA level, imaging, and/or biopsy, and then moving on to deciding on a treatment plan. The recent appearance of Coronavirus Disease 2019 has had an impact on both diagnosis and treatment methods. The diagnosis tests were reduced during the pandemic due to the fear of COVID. This has moderately affected the global prostate cancer biomarker market due to limitations to avoid transmission of COVID.
Based on Assay Type, the urine segment is expected to dominate the market growth
Because the prostate-specific antigen test lacks specificity for the identification of prostate cancer and can lead to unnecessary prostate biopsies, more specific biomarkers for prostate cancer and/or high-risk prostate cancer are needed. Urine is a viable source for developing novel prostate cancer. Prostate cancer is secreted into the prostatic secretions and eventually into the urine. After prostate modification, urine is enriched with Diagnostic prostate cancer biomarker biomarkers, such as prostate cancer cells, DNAs, RNAs, proteins, and other tiny molecules. The urine c prostate cancer antigen 3 test is the first RNA-based urinary marker approved by the Food and Drug Administration. It aids in the detection of prostate cancer during repeat biopsy. The SelectMDx test detects DLX1 and HOXC6 messenger RNA in urine after prostate massage and aids in diagnosing high-risk prostate cancer on prostate biopsy. Exosomes are extracellular vesicles that range in size from 30 to 200 nanometers in diameter and are released by various cell types.
Exosomes generated from urinary prostate cancer contain RNAs and proteins specific to prostate cancer (e.g., PCA3 and TMPRSS2-ERG), and could be useful for finding new biomarkers. The ExoDx Prostate test is a commercially available test that detects three genes in urine exosomes (PCA3, ERG, and SPDEF). Thanks to advances in comprehensive analysis, several urine biomarkers have been discovered (microarray, mass spectrometry, and next-generation sequencing). Non-invasive urine indicators can aid in the choice to do a prostate biopsy or the formulation of a treatment plan.
PCA3 has been the first true urine biomarker for a prostate cancer biomarker, thanks to FDA approval. Investigators have developed a second urine test based on TMPRSS2: erg fusion using the same technology.
The market growth in this region is expected to dominate owing to the rising incidence of prostate cancer, awareness about the disease and increasing diagnostic procedures for screening of prostate cancer.
According to CDC, prostate cancer is a disease that affects all males. prostate cancer affects roughly 13 out of every 100 American men at some point in their lives, and 2 to 3 men die from it. Every September in North America, health experts, health advocates, and those concerned with men's prostate health and Diagnostic prostate cancer biomarker observe National Prostate Health Month (NPHM), also known as National prostate cancer Awareness Month.
The global prostate cancer biomarker market is highly competitive with increasing demand for screening procedures for prostate cancer and increasing diagnostic procedures.
Some major key players in the global prostate cancer biomarker Market are: BioVision Inc., QIAGEN N.V., Roche Diagnostics Limited, Beckman Coulter Inc and Myriad Genetics, Sanofi-Aventis, Pfizer Inc, MDx Health.
The global prostate cancer biomarker market report would provide an access to an approx. 37 market data table, 36 figures and 180 pages.